Taiwan
· Delayed Price · Currency is TWD TaiMed Biologics Company Description
TaiMed Biologics Inc., a biotechnology company, develops, manufactures, and commercializes drugs for the treatment and prevention of infectious diseases.
It develops and markets Ibalizumab (TMB-355) Intravenous Infusion, a humanized monoclonal antibody for the treatment of HIV-1 infection.
It is also developing TMB-355 Intravenous Push, a humanized monoclonal antibody for the treatment of HIV-1 infection; TMB-355 Intramuscular Injection, a humanized monoclonal antibody intramuscular injection, which is in Phase III clinical trials for treating HIV-1; TMB-365, an anti-CD4 recombinant humanized monoclonal antibody, which completed Phase I clinical trials for treating HIV infections; and TMB-365/TMB-380, a neutralizing HIV-1 antibody.
The company was incorporated in 2007 and is headquartered in Taipei, Taiwan.
| Country | Taiwan |
| Founded | 2007 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Chin-Ming Chang |
Contact Details
Address: No. 607, Ruiguang Road Taipei, 11492 Taiwan | |
| Phone | 886 2 2658 0058 |
| Website | taimedbiologics.com |
Stock Details
| Ticker Symbol | 4147 |
| Exchange | Taipei Exchange |
| Fiscal Year | January - December |
| Reporting Currency | TWD |
| ISIN Number | TW0004147004 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Chin-Ming Chang Ph.D. | President and Chief Executive Officer |
| Dr. David D. Ho M.D. | Scientific Co-Founder, Chief Scientific Advisor and Board Director |
| Dr. Ing-Wen Tsai Ph.D. | Co-Founder |
| Dr. Lan-Bo Chen Ph.D. | Co-Founder |
| Jack Chen | Chief Financial Officer and Chief of Corporate Governance |